financetom
Business
financetom
/
Business
/
GlobalFoundries, Navitas Semiconductor to Collaborate on GaN Manufacturing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
GlobalFoundries, Navitas Semiconductor to Collaborate on GaN Manufacturing
Nov 20, 2025 7:57 AM

09:10 AM EST, 11/20/2025 (MT Newswires) -- GlobalFoundries ( GFS ) and Navitas Semiconductor ( NVTS ) said Thursday they have entered a long-term collaboration to expand US development and production of gallium nitride, or GaN, technology for high-power applications.

Financial terms were not provided.

The companies said the collaboration will focus on advancing GaN design and manufacturing for uses such as AI data centers, computing, energy systems, and industrial power equipment.

Navitas will contribute its device expertise, while GlobalFoundries ( GFS ) will provide large-scale manufacturing, according to the statement.

The companies said development is slated to start in early 2026 with production targeted for later that year.

Shares of GlobalFoundries ( GFS ) were up 2% in recent Thursday premarket activity, while Navitas Semiconductor ( NVTS ) stock rose 11%.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Qualcomm considers takeover offer for UK's Alphawave
Qualcomm considers takeover offer for UK's Alphawave
Apr 1, 2025
April 1 (Reuters) - Chipmaker Qualcomm said on Tuesday it is considering making an offer to acquire UK-based Alphawave IP Group ( AWEVF ). ...
Apellis Pharmaceuticals Says US FDA Grants Priority Review to Empaveli Application for Rare Kidney Diseases
Apellis Pharmaceuticals Says US FDA Grants Priority Review to Empaveli Application for Rare Kidney Diseases
Apr 1, 2025
09:05 AM EDT, 04/01/2025 (MT Newswires) -- Apellis Pharmaceuticals ( APLS ) said Tuesday that the US Food and Drug Administration has accepted its supplemental new drug application for Empaveli, or pegcetacoplan, to treat C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis, both rare kidney diseases. The company said the application is based on results from a late-stage trial that...
Roblox announces new ad format, Google partnership to boost advertising business
Roblox announces new ad format, Google partnership to boost advertising business
Apr 1, 2025
(Reuters) - Roblox ( RBLX ) on Tuesday launched a new format of video advertising on its gaming platform and announced a partnership with Google to help boost the growth of its nascent ad business. Gamers can choose to watch video advertisement, up to 30 seconds long, in exchange for boosts, lifelines or resources in a particular game through rewarded...
Compass Therapeutics Says its Ongoing Biliary Tract Cancer Combination Drug Trial Indicates Statistically Significant Overall Response Rate
Compass Therapeutics Says its Ongoing Biliary Tract Cancer Combination Drug Trial Indicates Statistically Significant Overall Response Rate
Apr 1, 2025
09:03 AM EDT, 04/01/2025 (MT Newswires) -- Compass Therapeutics ( CMPX ) said Tuesday topline data from an ongoing phase 2/3 trial of tovecimig combined with paclitaxel in biliary tract cancer showed 'statistically significant' improvement in overall response rate, indicating it has met the trial's primary efficacy endpoint. The drug combination achieved a 17.1% ORR, including one complete response, versus...
Copyright 2023-2026 - www.financetom.com All Rights Reserved